Acknowledgment of Reviewers
In This Issue/Research Watch/News in Brief/News from the IASLC Tobacco Control Committee
Plasma-Based Tumor Genetics for Monitoring Disease Progression
ALK FISH and IHC
Comparisons between Mouse and Human Studies Will Help the Prevention, Diagnosis, and Treatment of the Deadliest Type of Lung Cancer
The Comparative Pathology of Genetically Engineered Mouse Models for Neuroendocrine Carcinomas of the Lung
High Incidence of Somatic BAP1 Alterations in Sporadic Malignant Mesothelioma
Stereotactic Ablative Radiotherapy for Centrally Located Early Stage Non–Small-Cell Lung Cancer
Cost-Effectiveness of Multiplexed Predictive Biomarker Screening in Non-Small-Cell Lung Cancer
ALK Testing in Lung Adenocarcinoma
Dynamic Plasma EGFR Mutation Status as a Predictor of EGFR-TKI Efficacy in Patients with EGFR-Mutant Lung Adenocarcinoma
Comparison of Methods in the Detection of ALK and ROS1 Rearrangements in Lung Cancer
Prognostic Impact of Preoperative Tumor Marker Levels and Lymphovascular Invasion in Pathological Stage I Adenocarcinoma and Squamous Cell Carcinoma of the Lung
Validation of a Multiprotein Plasma Classifier to Identify Benign Lung Nodules
Prognostic Impact and Clinicopathological Correlations of the Cribriform Pattern in Pulmonary Adenocarcinoma
Identification and Validation of Long Noncoding RNA Biomarkers in Human Non–Small-Cell Lung Carcinomas
Final Overall Survival Results from a Phase III, Randomized, Placebo-Controlled, Parallel-Group Study of Gefitinib Versus Placebo as Maintenance Therapy in Patients with Locally Advanced or Metastatic Non–Small-Cell Lung Cancer (INFORM; C-TONG 0804)
Phase II Study of Afatinib, an Irreversible ErbB Family Blocker, in EGFR FISH-Positive Non–Small-Cell Lung Cancer
Mitosis Trumps T Stage and Proposed International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification for Prognostic Value in Resected Stage 1 Lung Adenocarcinoma
Relationship Between Tumor Size and Survival in Non–Small-Cell Lung Cancer (NSCLC)
Modified Masaoka Stage and Size Are Independent Prognostic Predictors in Thymoma and Modified Masaoka Stage Is Superior to Histopathologic Classifications
Conditional Survival of Malignant Thymoma Using National Population-Based Surveillance, Epidemiology, and End Results (SEER) Registry (1973–2011)
Transient Hyperesthesia and Radicular Pain
A Novel, Highly Sensitive ALK Antibody 1A4 Facilitates Effective Screening for ALK Rearrangements in Lung Adenocarcinomas by Standard Immunohistochemistry
Life-Threatening Bronchomediastinal Fistula Complicating a First Cycle of Chemotherapy in a Stage IV NSCLC Case
Unexpectedly Fludeoxyglucose (18F) Avid Well-Differentiated Adenocarcinoma of the Lung
Rapid Response to Trastuzumab Emtansine in a Patient with HER2-Driven Lung Cancer
Novel Association of Elastofibroma with Aortic Stenosis
Adding Bevacizumab to Chemotherapy Effectively Control Radioresistant Brain Metastases in ALK-Positive Lung Adenocarcinoma